Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

B. Solomon · SciRah

Researcher profile · Semantic Scholar

B. Solomon

Share profile

B. Solomon — researcher profile on SciRah

h-index: 76
Works: 412
Citations: 46K

Most-cited papers

Lung cancer
A. Thai, B. Solomon, L. Sequist, J. Gainor +1 more
2021The Lancet1,120 citations
Semantic Scholar
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
A. Shaw, T. Bauer, F. de Marinis, E. Felip +10 more
2020New England Journal of Medicine859 citations Open access
Semantic Scholar
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
L. Hendriks, K. Kerr, J. Menis, T. Mok +8 more
2023Annals of Oncology805 citations Open access
Semantic Scholar
Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†.
L. Hendriks, K. Kerr, J. Menis, T. Mok +8 more
2023Annals of Oncology574 citations Open access
Semantic Scholar
Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration
A. Drilon, J. Clark, J. Weiss, S. Ou +17 more
2020Nature Medicine362 citations Open access
Semantic Scholar
RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
B. Solomon, L. Tan, Jessica J. Lin, Stephen Q. Wong +27 more
2020Journal of Thoracic Oncology258 citations Open access
Semantic Scholar
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Lauren Giuffrida, K. Sek, M. Henderson, Junyun Lai +15 more
2021Nature Communications207 citations Open access
Semantic Scholar
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
Junyun Lai, Sherly Mardiana, Imran G. House, K. Sek +16 more
2020Nature Immunology196 citations
Semantic Scholar
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study.
B. Solomon, T. Bauer, T. Mok, Geoffrey Liu +14 more
2022The Lancet Respiratory Medicine188 citations
Semantic Scholar
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
A. Drilon, V. Subbiah, O. Gautschi, P. Tomasini +14 more
2022Journal of Clinical Oncology177 citations Open access
Semantic Scholar
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
B. Solomon, T. Bauer, S. Ignatius Ou, Geoffrey Liu +11 more
2022Journal of Clinical Oncology106 citations Open access
Semantic Scholar
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
E. Felip, A. Shaw, A. Bearz, D. Camidge +10 more
2021Annals of Oncology106 citations Open access
Semantic Scholar
Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer
A. Schoenfeld, S. Antonia, M. Awad, E. Felip +14 more
2021Annals of Oncology89 citations Open access
Semantic Scholar
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
J. Desai, Gan K. Hui, C. Barrow, M. Jameson +23 more
2020Journal of Clinical Oncology82 citations Open access
Semantic Scholar
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Elizabeth Ahern, B. Solomon, R. Hui, N. Pavlakis +2 more
2021Journal for ImmunoTherapy of Cancer64 citations Open access
Semantic Scholar
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
B. Murray, E. Rogers, D. Zhai, W. Deng +9 more
2021Molecular Cancer Therapeutics56 citations Open access
Semantic Scholar
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
A. Shaw, A. Varghese, B. Solomon, D. Costa +8 more
202146 citations
Semantic Scholar
Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapy
J. Lai-Kwon, S. Heynemann, J. Flore, H. Dhillon +9 more
2021Journal of cancer survivorship40 citations Open access
Semantic Scholar
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
J. L. Leal, M. Alexander, M. Itchins, Gavin Wright +8 more
2021Clinical Lung Cancer37 citations
Semantic Scholar
TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival
D. Freudenstein, Cassandra Litchfield, F. Caramia, Gavin Wright +6 more
2020Cancers33 citations Open access
Semantic Scholar
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.
J. Mazières, L. Iadeluca, A. Shaw, B. Solomon +10 more
2022Lung Cancer28 citations Open access
Semantic Scholar
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
Peter K. H. Lau, B. Feran, Lorey K. Smith, A. Lasocki +19 more
2021Journal for ImmunoTherapy of Cancer27 citations Open access
Semantic Scholar
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary
A. Posner, O. Prall, T. Sivakumaran, D. Etemadamoghadam +30 more
2022Journal of Pathology25 citations Open access
Semantic Scholar
A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806
Gan K. Hui, M. Burge, B. Solomon, Sze T. Lee +12 more
2021Journal of Nuclear Medicine22 citations Open access
Semantic Scholar
Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC).
Trudy C. Wu, Annalise Stube, C. Felix, D. Oseguera +16 more
2023International Journal of Radiation Oncology, Biology, Physics21 citations
Semantic Scholar
Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations
B. Solomon, H. Loong, Y. Summers, Z. Thomas +6 more
2022ESMO Open18 citations Open access
Semantic Scholar
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer
B. Solomon, Cai-Cun Zhou, A. Drilon, Keunchil Park +14 more
202118 citations
Semantic Scholar
Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial.
R. Soo, Eng Huat Tan, H. Hayashi, T. Seto +9 more
2022Lung Cancer17 citations Open access
Semantic Scholar
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
M. Ahn, M. Mendoza, N. Pavlakis, T. Kato +17 more
2022Clinical Lung Cancer16 citations Open access
Semantic Scholar
Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease.
S. Ou, B. Solomon, A. Shaw, S. Gadgeel +6 more
2022Journal of Thoracic Oncology15 citations Open access
Semantic Scholar
Alectinib induces marked red cell spheroacanthocytosis in a near-ubiquitous fashion and is associated with reduced eosin-5-maleimide binding.
J. Kuzich, S. Heynemann, N. Geoghegan, Cindy Evelyn +7 more
2021Pathology (Sydney)15 citations
Semantic Scholar
Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC).
B. Besse, A. Drilon, B. Solomon, V. Subbiah +10 more
202115 citations
Semantic Scholar
Prognostic stratification of HPV associated oropharyngeal cancer based on CD103+ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomised trials.
D. Rischin, H. Mehanna, R. Young, M. Bressel +10 more
2022Annals of Oncology14 citations Open access
Semantic Scholar
TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements.
R. Doebele, Jessica J. Lin, M. Nagasaka, Viola W. Zhu +12 more
202014 citations
Semantic Scholar
Patient-reported quality of life and toxicity in unilateral and bilateral radiotherapy for early-stage human papillomavirus associated tonsillar carcinoma
Lachlan McDowell, G. Casswell, M. Bressel, K. Gough +10 more
2020Clinical and Translational Radiation Oncology14 citations Open access
Semantic Scholar
Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors
D. Tan, Toshio Shimizu, B. Solomon, R. Heist +19 more
2022Cancer Research13 citations
Semantic Scholar
1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
M. Brandão, J. Hiltermann, E. Wauters, B. Solomon +15 more
2023Annals of Oncology12 citations
Semantic Scholar
Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
A. Thai, A. Lim, B. Solomon, D. Rischin
2021Cancers12 citations Open access
Semantic Scholar
Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review
M. Tjong, A. Louie, P. Iyengar, B. Solomon +2 more
2021Translational Lung Cancer Research11 citations Open access
Semantic Scholar
Immunotherapy in oncogene addicted non-small cell lung cancer
L. McLean, J. L. Leal, B. Solomon, T. John
2020Translational Lung Cancer Research11 citations Open access
Semantic Scholar
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
P. Cheema, B. Cho, H. Freitas, M. Provencio +22 more
2023Future Oncology10 citations Open access
Semantic Scholar
Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study.
D. Tan, M. Thomas, D.-W. Kim, S. Szpakowski +11 more
2021Lung Cancer10 citations Open access
Semantic Scholar
Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
B. Solomon, T. Bauer, T. Mok, Geoffrey Liu +14 more
2022Cancer Research8 citations
Semantic Scholar
Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians
G. Chazan, F. Franchini, M. Alexander, S. Banerjee +11 more
2021ESMO Open8 citations Open access
Semantic Scholar
Standard-Dose Osimertinib in EGFR-Mutated Non–Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease
L. McLean, W. Faisal, S. Parakh, S. Kao +8 more
2021JCO Precision Oncology8 citations
Semantic Scholar
1387P Phase Ib study of LXH254 + LTT462 in patients with KRAS- or BRAF-mutant NSCLC
J. Wolf, D. Planchard, R. Heist, B. Solomon +8 more
20208 citations Open access
Semantic Scholar
Defining Resistance Mechanisms to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer (editorial re: Lin et al.).
L. Tan, B. Solomon
2020Annals of Oncology8 citations Open access
Semantic Scholar
Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC.
Cai-Cun Zhou, B. Solomon, M. Pérol
2024New England Journal of Medicine7 citations Open access
Semantic Scholar
979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study
A. Bearz, E. Felip, J. Mazières, F. de Marinis +7 more
2022Annals of Oncology7 citations Open access
Semantic Scholar
MA06.07 Patterns of Progression with Lorlatinib and Insights into Subsequent Anticancer Therapy Efficacy in Advanced ALK+ NSCLC
T. Mok, B. Solomon, M. Campelo, Y.-L. Wu +8 more
2024Journal of Thoracic Oncology6 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. Felip×8
Invite
E. Felip — researcher profile on SciRah
A. Drilon×8
Invite
A. Drilon — researcher profile on SciRah
A. Shaw×6
Invite
A. Shaw — researcher profile on SciRah
T. Bauer×6
Invite
T. Bauer — researcher profile on SciRah

×6

Invite

F. de Marinis — researcher profile on SciRah

Dong-Wan Kim×6

Invite

Dong-Wan Kim — researcher profile on SciRah

Invite

T. Mok — researcher profile on SciRah

Invite

R. Soo — researcher profile on SciRah

Geoffrey Liu×5

Invite

Geoffrey Liu — researcher profile on SciRah

J. Mazières×5

Invite

J. Mazières — researcher profile on SciRah

Invite

A. Polli — researcher profile on SciRah

Invite

H. Thurm — researcher profile on SciRah